Borna Sedigheh, Saeidi Fatemeh Mir
Department of Perinatology, Tehran University of Medical Sciences, Tehran, Iran.
J Obstet Gynaecol Res. 2007 Oct;33(5):631-4. doi: 10.1111/j.1447-0756.2007.00623.x.
The effectiveness of the management of preterm birth remains an important health care issue, especially when considering that more than two thirds of singleton neonatal death occurs in preterm labor. The purpose of this study was to compare oral celecoxib with intravenous magnesium sulfate as tocolytic.
This was a randomized study of patients who were between 24 and 34 weeks of gestation with preterm labor. One hundred and four pregnant women with preterm labor were randomly assigned to receive celecoxib 100 mg b.i.d. for 48 h or intravenous magnesium sulfate (MgSO4) for maximum of 48 h. Outcome variables included delay of delivery for 48 h and the incidence of side-effects. Data was analyzed using the Student t-test and the chi(2) test.
There was no difference between the groups over the course of the study in demographic characteristics, cervical examination and amniotic fluid index. Labor was arrested for 48 h was in 42 (81%) and 45 (87%) of the patients in the celecoxib and magnesium sulfate groups, respectively (p-0.298). There were no severe maternal or neonatal complications in either group.
Celecoxib is as effective as magnesium sulfate for primary tocolysis.
早产管理的有效性仍然是一个重要的医疗保健问题，尤其是考虑到超过三分之二的单胎新生儿死亡发生在早产分娩时。本研究的目的是比较口服塞来昔布与静脉注射硫酸镁作为宫缩抑制剂的效果。
这是一项针对妊娠24至34周且有早产迹象患者的随机研究。104名有早产迹象的孕妇被随机分配接受塞来昔布100毫克，每日两次，共48小时，或静脉注射硫酸镁（MgSO4），最长48小时。观察变量包括分娩延迟48小时以及副作用发生率。数据采用学生t检验和卡方检验进行分析。
在研究过程中，两组在人口统计学特征、宫颈检查和羊水指数方面没有差异。塞来昔布组和硫酸镁组分别有42名（81%）和45名（87%）患者的宫缩停止了48小时（p = 0.298）。两组均未出现严重的母体或新生儿并发症。
塞来昔布作为一线宫缩抑制剂与硫酸镁效果相当。
